Cmp:612
Target:900
Duration:6-9 months.
Traded in:NSE-Bse
Story:At the
end of FY07, the company had 13 products in the US market and 36 ANDAs pending approval.These will help sustain its growth in the US market.The company has acquired seven pharmaceutical brands in Poland from Iceland-based Actavis and its affiliate Biovena for an undisclosed sum.The acquisition will give Glenmark an entry point into Poland and apart from opening up newer geographies, it will allow the company to replicate its domestic product portfolio in the region.Glenmark estimates sales of $15 million from the seven brands for 2008-09 with a 20 per cent growth in 2009-10.The changing business mix will also help improve its margins, going forward.The company is expected to deliver an EPS of Rs 52 for FY09.I am quite bullish on the company and this is one of the few pharma stocks which i like a lot.One of the best and safest pharma dose to prove a world of good for your portfolio.2)Scripscan:-SAAG RR Infra Ltd
Code:-531374
Cmp:39
Target:80
Duration:12-15 months
Story:-SAAG RR Infra Ltd is engaged in execution of infrastructure projects like water and sewer works and construction of specialised buildings (industrial, commercial and residential), roads and oil & gas pipeline construction and has positioned itself to take advantage of the growing demand in the oil & gas sector. The company has recently bagged a huge order of 288crs from ONGC for its charter hire of offshore modular workover rig 'SAAG Pacific' and for charter hire of offshore modular workover rig 'SAAG Saffron' to be executed over the next 3years.The company reported a revenue of about 66crs in all over fiscal 07-08.These order alone covers the sales by more than 4 times and gives a robust revenue visibility going foreward.The company has also has won projects from prestigious public sector and MNC clients including ISRO, NTPC, ICMR, BEML, HPCL, CMWSSB, B Braun Medical India and Degremont.The company is currently executing projects for puravankara projects,hiranandani realtors and mantri developers which are multi million dollar development projects in real estate.The company has been very aggresive in acquiring companies and if the sources are to be beleived then it has lined up few more major acquisitions in the coming few months.The company hasnt been an institutional fancy but there are news of research head of brokerages and mfs being in active talks with the management.Once gets covered may just go beyond reach.SAAG has been long overlooked in the bourses and virtually it never had a run over the last 3 years bull run.With these latest developments the company is sure to buzz a lot.A solid company to go for.
3)Scripscan:-Karuturi Global Ltd
Cmp:23
Target:40
Duration:12-15 months.
Traded in:Nse-Bse
Story:Karuturi Global is the world's largest producer of roses, cultivating 585 million stems per annum.It has over a decade of experience in rose cultivation with operations in Ethiopia, Kenya and India.The growth of an organised retail industry in the country is currently in a nascent stage of development and that will lead to a robust growth for cut-rose producers.The global supply-demand mismatch is considered to be positive for rose producers. Rise in per capita income and strong demand during festivals and Valentine's Day are fuelling huge flower consumption in India.The Indian floriculture sector is expected to grow by 40% each year (significantly higher than the global average) and almost 85% of the demand is estimated to be from roses.All these factors are expected to catapult karuturi in the top league.The revenues are expected to clock a 38 per cent CAGR over FY08-FY10 to Rs 770 crore with operating profit CAGR of 40 per cent to Rs 280 crore and a profit after tax CAGR of 52 per cent to Rs 240 crore.At present price of 23 the company is quoting at less than 6 times its fy10 earnings.Considering the huge potential of the company,karuturi is a must have.
